nach oben

Erschienen in:

01.09.2009 | Original Article

Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer

verfasst von: Alessandra Battaglia, Alexia Buzzonetti, Cinzia Baranello, Gabriella Ferrandina, Enrica Martinelli, Francesco Fanfani, Giovanni Scambia, Andrea Fattorossi

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Abstract

Objective

We compared the immune system state in metastatic tumour draining lymph nodes (mTDLN) and metastasis free TDLN (mfTDLN) in 53 early stage cervical cancer patients to assess whether the presence of metastatic tumour cells worsen the balance between an efficacious anti-tumour and a tolerogenic microenvironment.

Methods

The immune system state was measured by immunophenotypic and functional assessment of suppressor and effector immune cell subsets.

Results

Compared to mfTDLN, mTDLN were significantly enriched in CD4⁺Foxp3⁺ regulatory T cells (Treg), which, in addition, exhibited an activated phenotype (HLA-DR⁺ and CD69⁺). Treg in mTDLN were also significantly enriched in neuropilin-1 (Nrp1) expressing cells, a subset particularly potent in dampening T cell responses. mTDLN tended to be enriched in a population of CD8⁺Foxp3⁺T cells (operationally defined as CD8⁺Treg) that showed a suppressor potency similar to Treg under the same experimental conditions. Plasmacytoid dendritic cells (pDC) and myeloid DC (mDC) generally show distinct roles in inducing T cell tolerance and activation, respectively. In line with the excess of suppressor T cells, the ratio pDC to mDC was significantly increased in mTDLN. Immunohistochemical testing showed that metastatic tumour cells produced the vascular endothelial growth factor, a natural ligand for Nrp1 expressed on the cell surface of Nrp1⁺Treg and pDC, and therefore a potential mediator by which tumour cells foster immune privilege in mTDLN. Consistent with the overall tolerogenic profile, mTDLN showed a significant Tc2 polarisation and tended to contain lower numbers of CD45RA⁺CD27⁻ effector memory CD8⁺T cells.

Conclusions

The increased recruitment of suppressor type cells concomitant with the scarcity of cytotoxic type cells suggests that in mTDLN the presence of tumour cells could tip the balance against anti-tumour immune response facilitating the survival of metastatic tumour cells and possibly contributing to systemic tolerance.

Baars PA, Ribeiro Do Couto LM, Leusen JH, Hooibrink B, Kuijpers TW, Lens SM, van Lier RA (2001) Cytolytic mechanisms and expression of activation-regulating receptors on effector-type CD8⁺CD45RA⁺CD27⁻ human T cells. J Immunol 165:1910–1917

Barbera-Guillem E, Nyhus JK, Wolford CC, Friece CR, Sampsel JW (2002) Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res 62:7042–7049PubMed

Battaglia A, Buzzonetti A, Monego G, Peri L, Ferrandina G, Fanfani F, Scambia G, Fattorossi A (2008) Neuropilin-1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by pre-operative chemoradiation therapy in cervical cancer. Immunology 123:129–138PubMedCrossRef

Battaglia A, Ferrandina G, Buzzonetti A, Malinconico P, Legge F, Salutari V, Scambia G, Fattorossi A (2003) Lymphocyte populations in human lymph nodes. Alterations in CD4⁺CD25⁺ T regulatory cell phenotype and T-cell receptor Vβ repertoire. Immunology 110:304–312PubMedCrossRef

Boor PP, Ijzermans JN, van der Molen RG, Binda R, Mancham S, Metselaar HJ, Kusters JG, de Jong E, Drexhage HA, Kwekkeboom J (2005) Immunomagnetic selection of functional dendritic cells from human lymph nodes. Immunol Lett 99:162–168PubMedCrossRef

Bourbié-Vaudaine S, Blanchard N, Hivroz C, Roméo PH (2006) Dendritic cells can turn CD4⁺ T lymphocytes into vascular endothelial growth factor-carrying cells by intercellular neuropilin-1 transfer. J Immunol 177:1460–1469PubMed

Bruder D, Probst-Kepper M, Westendorf AM, Geffers R, Beissert S, Loser K, von Boehmer H, Buer J, Hansen W (2004) Neuropilin-1: a surface marker of regulatory T cells. Eur J Immunol 34:623–630PubMedCrossRef

Bryan CF, Eastman PJ, Conner JB, Baier KA, Durham JB (1993) Clinical utility of a lymph node normal range obtained by flow cytometry. Ann N Y Acad Sci 677:404–406PubMedCrossRef

Carter LL, Dutton RW (1996) Type 1 and type 2: a fundamental dichotomy for all T-cell subsets. Curr Opin Immunol 8:336–342PubMedCrossRef

10.

Cochran AJ, Huang RR, Lee J, Itakura E, Leong SP, Essner R (2006) Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 6:659–670PubMedCrossRef

11.

Cosmi L, Liotta F, Lazzeri E, Francalanci M, Angeli R, Mazzinghi B, Santarlasci V, Manetti R, Vanini V, Romagnani P, Maggi E, Romagnani S, Annunziato F (2003) Human CD8⁺CD25⁺ thymocytes share phenotypic and functional features with CD4⁺CD25⁺ regulatory thymocytes. Blood 102:4107–4114PubMedCrossRef

12.

Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949PubMedCrossRef

13.

De Rosa SC, Herzenberg LA, Herzenberg LA, Roederer M (2001) 11-color, 13-parameter flow cytometry: identification of human naïve T cells by phenotype, function, and T-cell receptor diversity. Nat Med 7:245–248PubMedCrossRef

14.

Dercamp C, Chemin K, Caux C, Trinchieri G, Vicari AP (2005) Distinct and overlapping roles of interleukin-10 and CD25⁺ regulatory T cells in the inhibition of antitumour CD8 T-cell responses. Cancer Res 65:8479–8486PubMedCrossRef

15.

Dobrzanski MJ, Reome JB, Dutton RW (2000) Type 1 and type 2 CD8⁺ effector T cell subpopulations promote long-term tumour immunity and protection to progressively growing tumour. J Immunol 164:916–925PubMed

16.

Farzad Z, Cochran AJ, McBride WH, Gray JD, Wong V, Morton DL (1990) Lymphocyte subset alterations in nodes regional to human melanoma. Cancer Res 50:3585–3588PubMed

17.

Fattorossi A, Battaglia A, Ferrandina G, Buzzonetti A, Legge F, Salutari V, Scambia G (2004) Lymphocyte composition of tumour draining lymph nodes from cervical and endometrial cancer patients. Gynecol Oncol 92:106–115PubMedCrossRef

18.

Ferrandina G, Ranelletti FO, Legge F, Salutari V, Martinelli E, Fattorossi A, Lorusso D, Zannoni G, Vellone V, Paglia A, Scambia G (2006) Celecoxib up-regulates the expression of the zeta chain of T cell receptor complex in tumour-infiltrating lymphocytes in human cervical cancer. Clin Cancer Res 12:2055–2060PubMedCrossRef

19.

Ferrandina G, Legge F, Fagotti A, Fanfani F, Distefano M, Morganti A, Cellini N, Scambia G (2007) Preoperative concomitant chemoradiotherapy in locally advanced cervical cancer: safety, outcome, and prognostic measures. Gynecol Oncol 107:S127–S132PubMedCrossRef

20.

Fisson S, Darrasse-Jèze G, Litvinova E, Septier F, Klatzmann D, Liblau R, Salomon BL (2003) Continuous activation of autoreactive CD4⁺ CD25⁺ regulatory T cells in the steady state. J Exp Med 198:737–746PubMedCrossRef

21.

Fuh GK, Garcia C, de Vos AM (2000) The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor Flt-1J. Biol Chem 275:26690–26695

22.

Green J, Kirwan J, Tierney J, Vale C, Symonds P, Fresco L, Williams C, Collingwood M (2005) Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev 3:CD002225

23.

Houvenaeghel G, Lelievre L, Gonzague-Casabianca L, Buttarelli M, Moutardier V, Goncalves A, Resbeut M (2006) Long-term survival after concomitant chemoradiotherapy prior to surgery in advanced cervical carcinoma. Gynecol Oncol 100:338–343PubMedCrossRef

24.

Imai T, Nagira M, Takagi S, Kakizaki M, Nishimura M, Wang J, Gray PW, Matsushima K, Yoshie O (1999) Selective recruitment of CCR4-bearing Th2 cells toward antigen presenting cells by the CC chemokine thymus and activation regulated chemokine and macrophage-derived chemokine. Int Immunol 11:81–88PubMedCrossRef

25.

Jandus C, Bioley G, Speiser DE, Romero P (2008) Selective accumulation of differentiated FOXP3(+) CD4(+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood. Cancer Immunol Immunother 57:1795–1805PubMedCrossRef

26.

Jarvis LB, Matyszak MK, Duggleby RC, Goodall JC, Hall FC, Gaston JS (2005) Autoreactive human peripheral blood CD8⁺ T cells with a regulatory phenotype and function. Eur J Immunol 35:2896–2908PubMedCrossRef

27.

Joosten SA, van Meijgaarden KE, Savage ND, de Boer T, Triebel F, van der Wal A, de Heer E, Klein MR, Geluk A, Ottenhoff TH (2007) Identification of a human CD8⁺ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc Natl Acad Sci USA 104:8029–8034PubMedCrossRef

28.

Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, van der Burg SH, Melief CJ (2008) Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 1:169–177CrossRef

29.

Kim R, Emi M, Tanabe K, Arihiro K (2007) Potential functional role of plasmacytoid dendritic cells in cancer immunity. Immunology 121:149–157PubMedCrossRef

30.

Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM, Thompson TC, Old LJ, Wang RF (2007) CD8⁺ Foxp3⁺ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 13:6947–6958PubMedCrossRef

31.

Kohrt HE, Nouri N, Nowels K, Johnson D, Holmes S, Lee PP (2005) Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med 2:e284PubMedCrossRef

32.

Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4⁺ T reg cells. J Exp Med 203:1701–1711PubMedCrossRef

33.

Miyajima A (1997) CDw123 (Interleukin3 receptor alpha chain) Workshop Panel Report. In: Kishimoto T et al (eds) Leukocyte typing VI, white cell differentiation antigens, Garland Science Publishing, Inc., UK, pp 854–855

34.

Munn DH, Mellor AL (2006) The tumour-draining lymph node as an immune-privileged site. Immunol Rev 213:146–158PubMedCrossRef

35.

Ohm JE, Carbone DP (2001) VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 23:263–272PubMedCrossRef

36.

Pacanowski J, Kahi S, Baillet M, Lebon P, Deveau C, Goujard C, Meyer L, Oksenhendler E, Sinet M, Hosmalin A (2001) Reduced blood CD123⁺ (lymphoid) and CD11c⁺ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood 98:3016–3021PubMedCrossRef

37.

Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW, Melief CJ, Kenter GG, Fleuren GJ, Offringa R, van der Burg SH (2007) High number of intraepithelial CD8⁺ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 67:354–361PubMedCrossRef

38.

Piver MS, Rutledge F, Smith JP (1974) Five classes of extended hysterectomy. Obstet Gynecol 44:265–272PubMed

39.

Popescu I, Macedo C, Abu-Elmagd K, Shapiro R, Hua Y, Thomson AW, Morelli AE, Storkus WJ, Metes D (2007) EBV-specific CD8+ T cell reactivation in transplant patients results in expansion of CD8+ type-1 regulatory T cells. Am J Transplant 7:1215–1223PubMedCrossRef

40.

Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, Koch AE, Moser B, Mackay CR (1998) The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 101:746–754PubMedCrossRef

41.

Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal Malefyt R, Liu YJ (1999) Reciprocal control of T helper cell and dendritic cell differentiation. Science 283:1183–1186PubMedCrossRef

42.

Rostaing L, Tkaczuk J, Durand M, Peres C, Durand D, de Préval C, Ohayon E, Abbal M (1999) Kinetics of intracytoplasmic Th1 and Th2 cytokine production assessed by flow cytometry following in vitro activation of peripheral blood mononuclear cells. Cytometry 35:318–328PubMedCrossRef

43.

Sakaguchi S, Wing K, Miyara M (2007) Regulatory T cells—a brief history and perspective. Eur J Immunol 37(Suppl 1):S116–S123PubMedCrossRef

44.

Sallusto F, Mackay C, Lanzavecchia A (1997) Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 277:2005–2007PubMedCrossRef

45.

Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R, Roman JJ, Burnett A, Pecorelli S, Cannon MJ (2006) HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol 100:469–478PubMedCrossRef

46.

Shurin MR, Shurin GV, Lokshin A, Yurkovetsky ZR, Gutkin DW, Chatta G, Zhong H, Han B, Ferris RL (2006) Intratumoural cytokines/chemokines/growth factors and tumour infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev 25:333–356PubMedCrossRef

47.

Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M, Shimizu J, Sakaguchi S (1998) Immunologic self-tolerance maintained by CD25⁺CD4⁺ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 10:1969–1980PubMedCrossRef

48.

Tang Q, Bluestone JA (2006) Plasmacytoid DCs and T(reg) cells: casual acquaintance or monogamous relationship? Nat Immunol 7:551–553PubMedCrossRef

49.

Tang X, Smith TR, Kumar V (2005) Specific control of immunity by regulatory CD8 T cells. Cell Mol Immunol 2:11–19PubMed

50.

Upham JW, Lundahl J, Liang H, Denburg JA, O’Byrne PM, Snider DP (2000) Simplified quantitation of myeloid dendritic cells in peripheral blood using flow cytometry. Cytometry 40:50–59PubMedCrossRef

51.

van der Burg SH, Piersma SJ, de Jong A, van der Hulst JM, Kwappenberg KM, van den Hende M, Welters MJ, Van Rood JJ, Fleuren GJ, Melief CJ, Kenter GG, Offringa R (2007) Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci USA 104:12087–12092PubMedCrossRef

52.

Vidal-Rubio B, Sanchez-Carril M, Oliver-Morales J, González-Femandez A, Gambón-Deza F (2001) Changes in human lymphocyte subpopulations in tonsils and regional lymph nodes of human head and neck squamous carcinoma compared to control lymph nodes. BMC Immunol 2:2PubMedCrossRef

53.

Viguier M, Lemaître F, Verola O, Cho MS, Gorochov G, Dubertret L, Bachelez H, Kourilsky P, Ferradini L (2004) Foxp3 expressing CD4+ CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 15:1444–1453

54.

Yagi H, Nomura T, Nakamura K, Yamazaki S, Kitawaki T, Hori S, Maeda M, Onodera M, Uchiyama T, Fujii S, Sakaguchi S (2004) Crucial role of FOXP3 in the development and function of human CD25⁺CD4⁺ regulatory T cells. Int Immunol 16:1643–1656PubMedCrossRef

55.

Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263–274PubMedCrossRef

Titel: Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer
verfasst von: Alessandra Battaglia
Alexia Buzzonetti
Cinzia Baranello
Gabriella Ferrandina
Enrica Martinelli
Francesco Fanfani
Giovanni Scambia
Andrea Fattorossi
Publikationsdatum: 01.09.2009
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 9/2009
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-008-0646-7

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer

Abstract

Objective

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

HNO-Op. auch mit über 90?

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2009

Acknowledgement

Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines

Soluble HLA/peptide monomers cross-linked with co-stimulatory antibodies onto a streptavidin core molecule efficiently stimulate antigen-specific T cell responses

Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable?

Toll-like receptor expression in normal ovary and ovarian tumors

HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

HNO-Op. auch mit über 90?

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Onkologie